Moreover, individualized dosing strategies can help mitigate the risk of common side effects, such as nausea and gastrointestinal discomfort, which are often associated with higher doses in standard treatment protocols
The safety of NOVOLOG was evaluated in two treat-to-target trials of 6 months duration, conducted in patients with type 1 diabetes or type 2 diabetes [see Clinical Studies (14)]
This article breaks down what most doctors still don't know: the black box warning on hormone therapy was removed, brain fog is neuroinflammation (not normal), and what gets dismissed as inevitable is actually preventable metabolic and vascular dysfunction
Lintsen AME, Braat DDM, Habbema JDF, et al
Drucker, who is an endocrinologist, Banting and Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology and professor of medicine in the division of endocrinology at University of Toronto and has a laboratory based in the Lunenfeld Tanenbaum Research Institute at Mount Sinai Hospital in Toronto, said GLP-1s have gone from scientists questioning why anyone would want to use an injectable sulfonylurea to a class of drugs that have numerous benefits, including: reductions in albuminuria, atherosclerosis, body weight, blood pressure, cell death, fibrosis, glucose, gut motility, inflammation, oxidative stress, platelet aggregation, postprandial lipemia and thrombosis
